Investors

Deerfield

deerfield_logo_k

Deerfield is a leading investment management firm committed to advancing healthcare through investment, information and philanthropy.

Deerfield was launched in 1994 with approximately $17 million in capital and, as of January 2014, manages funds in excess of $3.5 billion. It is a relationship-focused, non-activist firm that is committed to helping the companies in which it invests to realize their potential for advancing healthcare and driving change in this crucial industry. Deerfield’s comprehensive understanding of healthcare assets allows it to appreciate opportunity even when complex financial, legislative, regulatory and competitive pressures are present. Collaboration, intellectual curiosity and pragmatism define its approach.

Deerfield has over 70 full-time professionals who bring many decades of experience across all sub-sectors of healthcare in order to deliver innovative funding solutions to the firm’s financing partners. For more information about Deerfield, please visit www.deerfield.com.

Milestone Venture Partners

Milestone Venture Partners is an early stage venture capital fund with $90 million under management. Milestone concentrates on companies that solve business problems and address consumer needs through the innovative application of information technology. Milestone invests approximately 50% of its capital in Digital Health businesses which provide information services to hospitals, physicians, pharmaceutical firms, health plans and consumers. To learn more visit www.milestonevp.com.

New Leaf Venture Partners

NEW LEAF VENTURE PARTNERS is a leading healthcare technology investor, managing approximately $1 billion in funds, and investments in 45 companies. They focus on 3 sectors: biopharmaceuticals, medical devices, and diagnostic/infrastructure technologies. Their goal is to build strong companies by supporting exceptional teams in the development of clinically important and commercially attractive products.

Across all sectors and stages, their investment decisions are primarily driven by a fundamental assessment of the risks in the underlying development programs (i.e., technical, clinical, regulatory, and commercial risks). Before making an investment, they work with the management teams to identify key milestones that must be met to reach points of meaningful value inflection, and they ensure that adequate resources are provided for the company to achieve those milestones.

The NLV investment team has deep operating experience and medical and technical expertise which are integral to their active investment approach. This allows them to work closely with founders, management, and co-investors to identify and execute on a capital efficient and optimal path to value creation and exit. This focused and fundamentals driven investment approach generates attractive returns for their investors.

NLV Partners has offices in New York and Menlo Park, California. They are currently making new investments through New Leaf Ventures II, a $450 million fund, which started its investing cycle in mid-2008. To learn more visit www.nlvpartners.com.

Partnership Fund for New York City

 

FUND-logo-PMS-CoolGray11_coated 333x64

Founded by Henry Kravis of Kohlberg Kravis Roberts & Co. in 1996 with funding from New York’s leaders of business and finance, the Partnership Fund for New York City mobilizes its investors resource — their money, time and influence — to create jobs, spur new business creation and to expand opportunities for all of the city’s residents and neighborhoods. An “evergreen” fund, realized gains are continuously reinvested. Since inception, the Fund has invested in excess of $150 million. Investments are made only in NYC-based enterprises principally in the areas of digital health, financial technology, life sciences, advanced manufacturing, healthcare, workforce development and food manufacturing.

To learn more visit fund.pfnyc.org.

Safeguard Scientifics

Safeguard - Logo - V1

Safeguard Scientifics provides growth capital for entrepreneurial and innovative life sciences and technology companies. Safeguard targets life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices, Regenerative Medicine and Specialty Pharmaceuticals, and technology companies in Internet / New Media, Financial Services IT and Healthcare IT with capital requirements of up to $25 million. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings.

Safeguard has deployed capital in and provided operational expertise and support to hundreds of companies, entrepreneurs and management teams, successfully completing more than 100 M&A transactions and 20 IPOs. Safeguard’s prudent and innovative approach to identifying market leaders in key strategic sectors has spawned household names and industry leaders including Novell, QVC, Cambridge Technology Partners, Internet Capital Group, CompuCom Systems and Traffic.com. To learn more visit www.safeguard.com.